Skip to main content
SpringerLink
Log in

HER2-Targeted Therapy in Osteosarcoma

  • Chapter
  • First Online:
Book cover Current Advances in Osteosarcoma

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1257))

Abstract

In this chapter, we will review studies of HER2 in osteosarcoma and discuss the controversies that have existed in this field. Our present understanding of HER2 in the context of osteosarcoma is that it is expressed on a subset of patient samples, but that expression is not prognostic. We will review the two trials that have been conducted in osteosarcoma which have targeted HER2. Use of an antibody, trastuzumab, did not suggest activity, but a smaller study using HER2-targeted CAR T cells suggested activity may be present. A trial of an antibody–drug conjugate targeting HER2 for recurrent osteosarcoma is under consideration. Trials targeting other surface proteins for the treatment of osteosarcoma have occurred or are in development. Indeed, this leads us to discuss in a broader fashion therapeutic approaches to targeting surface proteins. It is hoped that some of these approaches will lead to new effective therapies for patients with osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312(5994):513–516

    Article  CAS  PubMed  Google Scholar 

  2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230(4730):1132–1139

    Article  CAS  PubMed  Google Scholar 

  3. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555):394–398

    Article  CAS  PubMed  Google Scholar 

  4. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237(4811):178–182

    Article  PubMed  Google Scholar 

  5. Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84(20):7159–7163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89(22):10578–10582

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT (2004) Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64(6):2047–2053

    Article  CAS  PubMed  Google Scholar 

  8. Hassan SE, Bekarev M, Kim MY, Lin J, Piperdi S, Gorlick R et al (2012) Cell surface receptor expression patterns in osteosarcoma. Cancer 118(3):740–749

    Article  CAS  PubMed  Google Scholar 

  9. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M et al (2005) Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur J Cancer 41(9):1349–1361

    Article  CAS  PubMed  Google Scholar 

  10. Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A et al (1996) ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77(1):71–78

    Article  CAS  PubMed  Google Scholar 

  11. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG et al (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16(7):2452–2458

    Article  CAS  PubMed  Google Scholar 

  12. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH et al (1999) Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17(9):2781–2788

    Article  CAS  PubMed  Google Scholar 

  13. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE (2003) Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25(1):27–32

    Article  PubMed  Google Scholar 

  14. Fellenberg J, Krauthoff A, Pollandt K, Delling G, Parsch D (2004) Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Investig 84(1):113–121

    Article  CAS  PubMed  Google Scholar 

  15. Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M et al (2004) Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 100(9):1936–1942

    Article  CAS  PubMed  Google Scholar 

  16. Maitra A, Wanzer D, Weinberg AG, Ashfaq R (2001) Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92(3):677–683

    Article  CAS  PubMed  Google Scholar 

  17. Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH et al (2001) Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14(12):1277–1283

    Article  CAS  PubMed  Google Scholar 

  18. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L (2002) Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin Cancer Res 8(3):788–793

    CAS  PubMed  Google Scholar 

  19. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M et al (2004) Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40(7):963–970

    Article  CAS  PubMed  Google Scholar 

  20. Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S et al (2004) HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Investig 22(1):16–24

    Article  CAS  Google Scholar 

  21. Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS (2005) HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 8(5):525–532

    Article  CAS  PubMed  Google Scholar 

  22. Willmore-Payne C, Holden JA, Zhou H, Gupta D, Hirschowitz S, Wittwer CT et al (2006) Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions. Arch Pathol Lab Med 130(5):691–698

    Article  CAS  PubMed  Google Scholar 

  23. Bakhshi S, Gupta A, Sharma MC, Khan SA, Rastogi S (2009) Her-2/neu, p-53, and their coexpression in osteosarcoma. J Pediatr Hematol Oncol 31(4):245–251

    Article  CAS  PubMed  Google Scholar 

  24. Gorlick S, Barkauskas DA, Krailo M, Piperdi S, Sowers R, Gill J et al (2014) HER-2 expression is not prognostic in osteosarcoma; a Children’s Oncology Group prospective biology study. Pediatr Blood Cancer 61(9):1558–1564

    Article  PubMed  PubMed Central  Google Scholar 

  25. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K et al (2002) ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94(5):1397–1404

    Article  CAS  PubMed  Google Scholar 

  26. Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki S, Ishii S (2001) Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 60(4):361–366

    Article  CAS  PubMed  Google Scholar 

  27. Li YG, Geng X (2010) A meta-analysis on the association of HER-2 overexpression with prognosis in human osteosarcoma. Eur J Cancer Care (Engl) 19(3):313–316

    Article  CAS  Google Scholar 

  28. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792

    Article  CAS  PubMed  Google Scholar 

  29. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

    Article  CAS  PubMed  Google Scholar 

  30. Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE et al (2012) Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol 30(20):2545–2551

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Park JH, Geyer MB, Brentjens RJ (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127(26):3312–3320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS et al (2009) Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 17(10):1779–1787

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM et al (2012) Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther 19(3):212–217

    Article  CAS  PubMed  Google Scholar 

  34. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H et al (2018) Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell 9(10):838–847

    Article  CAS  PubMed  Google Scholar 

  36. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D et al (2017) HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 3(8):1094–1101

    Article  PubMed  PubMed Central  Google Scholar 

  37. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C et al (2015) Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33(15):1688–1696

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y et al (2017) DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer 141(8):1682–1689

    Article  CAS  PubMed  Google Scholar 

  39. Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K et al (2017) Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol 18(11):1512–1522

    Article  CAS  PubMed  Google Scholar 

  40. Abdou AG, Kandil M, Asaad NY, Dawoud MM, Shahin AA, Abd Eldayem AF (2016) The prognostic role of Ezrin and HER2/neu expression in osteosarcoma. Appl Immunohistochem Mol Morphol 24(5):355–363

    Article  CAS  PubMed  Google Scholar 

  41. Ma Q, Zhou Y, Ma B, Chen X, Wen Y, Liu Y et al (2012) The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: a pilot study. Oncol Lett 3(4):797–801

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Jonathan Gill, Pooja Hingorani, Michael Roth & Richard Gorlick

Authors
  1. Jonathan Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pooja Hingorani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Gorlick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Gorlick .

Editor information

Editors and Affiliations

  1. Department of Pediatric Research, Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Eugenie S. Kleinerman

  2. Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Richard Gorlick

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gill, J., Hingorani, P., Roth, M., Gorlick, R. (2020). HER2-Targeted Therapy in Osteosarcoma. In: Kleinerman, E.S., Gorlick, R. (eds) Current Advances in Osteosarcoma . Advances in Experimental Medicine and Biology, vol 1257. Springer, Cham. https://doi.org/10.1007/978-3-030-43032-0_5

Download citation

Publish with us

Policies and ethics

Search

Navigation